Lerda Casaccia, Tiago
Hefner, Simon
Strauss, Jonas
Bieler, Lara
Dariia, Kliushnikova
Gabriel, Maria
Hitzl, Wolfgang
Trinka, Eugen
Wipfler, Peter
Moser, Tobias
Article History
Received: 10 September 2024
Accepted: 17 March 2025
First Online: 19 March 2025
Declarations
:
: E.T. has received consultancy fees from Arvelle Therapeutics, Argenx, Clexio, Celegene, UCB Pharma, Eisai, Epilog, Bial, Medtronic, Everpharma, Biogen, Takeda, Liva-Nova, Newbridge, Sunovion, GW Pharmaceuticals, and Marinus; speaker fees from Arvelle Therapeutics, Bial, Biogen, Böhringer Ingelheim, Eisai, Everpharma, GSK, GW Pharmaceuticals, Hikma, Liva-Nova, Newbridge, Novartis, Sanofi, Sandoz and UCB Pharma; research funding (directly, or to his institution) from GSK, Biogen, Eisai, Novartis, Red Bull, Bayer, and UCB Pharma outside the submitted work. He has received grants from Austrian Science Fund (FWF), Österreichische Nationalbank, and the European Union. E.T. is the CEO of Neuroconsult Ges.m.b.H. P.W. has participated in meetings sponsored by, received honoraria (lectures, advisory boards, consultations) or travel funding from Alexion, Biogen, Merck, Novartis, Roche, Sanofi-Genzyme, Teva-Ratiopharm, Janssen-Pharmazeutika, Bristol-Myers SQUIBB and Horizon Therapeutics. T.M. received travel support, honoraria for presentations or participation on advisory boards from Biogen, BMS, Novartis, Roche, Sanofi, Merck and Teva. The remaining authors report no conflict of interest.